Arbutus turns patent wins into cash and a big share buyback
New patent suits against Pfizer and BioNTech Arbutus and partner Genevant sued Pfizer and BioNTech in Canada and Europe over the lipid nanoparticle technology used in their COVID vaccine, seeking injunctions and damages. If Arbutus wins or settles, it could collect royalties or a lump sum, which would lift the stock.
This is the period's main new legal catalyst that could bring Arbutus more money.
Moderna pays $178M; up to $230M to shareholders Arbutus received about $178 million from its $950 million Moderna patent settlement and said it will return up to roughly $230 million to shareholders through buybacks. Real cash in hand and a plan to hand it back supports the share price.
It shows the patent money is real and being used to reward shareholders.
$230M tender offer at $5.00-$5.75 a share Arbutus launched a modified Dutch auction to buy back up to $230 million of stock at $5.00 to $5.75 per share, funded from cash on hand. A buyback at a set price can put a floor under the stock and signals management thinks it is cheap.
The buyback is the concrete action that moves the share price this period.
Buyback final: 46M shares at $5 each Arbutus will cancel about 46 million shares at $5 each, roughly 23% of the company, leaving nearly 153.3 million shares outstanding. Fewer shares means each remaining share owns more of the company, which can raise the value per share.
It is the completed result of the buyback and changes Arbutus's share count.